US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders ...

Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 ...

Japanese drugmaker Shionogi (TYO: 4507) has filed a supplemental application in Japan to broaden the use of its oral ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

US mRNA specialist Moderna today announced positive results from a Phase III efficacy study (P304) evaluating the relative ...

Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) ...

US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells ...

US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) last week submitted comments in response to the ...

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM: the USA, France, Germany, Italy, Span, the UK and Japan) is forecast to grow at a compound annual growth rate (CAGR) ...

China’s National Medical Products Administration (NMPA) has approved Innovent Biologics’ (HKEX: 01801) mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, ...

US biotech major Gilead Sciences (Nasdaq: GILD) has halted two mid-stage studies of its experimental antiviral obeldesivir after low rates of respiratory syncytial virus (RSV) infections undermined ...

In its ongoing mission to help meet America’s growing need for high-quality US-made medicines, London listed Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) announced its US unit will invest $1 ...